摘要
目的 研究丙泊酚对前列腺癌细胞(PC3)增殖、侵袭和凋亡及Nrf2/ARE通路的影响。方法 将PC3细胞分为空白对照组、丙泊酚低、中、高(2、4、6 mg/L)剂量组和阳性对照组(75 nmol/L阿霉素)。CCK-8法检测细胞存活率;改良Matrigel Boyden室法测定细胞侵袭力;流式细胞术检测细胞凋亡率;蛋白质印迹法检测核因子E2相关因子2(Nrf2)和抗氧化反应元件(ARE)蛋白表达。结果 与空白对照组比较,丙泊酚组和阳性对照组PC3细胞存活率、侵袭力、Nrf2和ARE蛋白表达水平均显著降低,细胞凋亡率显著升高,且效应呈丙泊酚剂量依赖性(P<0.05)。与阳性对照组比较,丙泊酚低剂量组和中剂量组PC3细胞存活率、侵袭力、Nrf2和ARE蛋白表达水平均显著升高,细胞凋亡率显著降低(P<0.05),而丙泊酚高剂量组差异无显著性(P>0.05)。结论 丙泊酚可有效逆转前列腺癌PC3细胞恶性生物学行为,其机制可能与抑制Nrf2/ARE信号通路相关蛋白表达有关。
Aim To study the effects of propofol on proliferation, invasion, apoptosis and Nrf2/ARE pathway of prostate cancer cell(PC3). Methods PC3 cell were divided into blank control group, propofol low, medium, high(2, 4, 6 mg/L) dose group and the positive control group(75 nmol/L doxorubicin), the cell survival rate was detected by CCK-8 method, the cell invasiveness was measured by modified Matrigel Boyden chamber method, the apoptosis rate was detected by flow cytometry, and the protein expressions of nuclear factor E2 related factor 2(Nrf2) and antioxidant response element(ARE) were detected by Western blot. Results Compared with the blank control group, the survival rate, invasiveness, Nrf2 and ARE protein expression levels of PC3 cell in propofol group and positive control group were significantly decreased, and the apoptosis rate was significantly increased. Compared with the positive control group, the survival rate, invasiveness, Nrf2 and ARE Protein expression levels of PC3 cell in the low-dose and medium-dose propofol groups were significantly increased, and the apoptosis rate was significantly decreased(P<0.05), but there was no significant difference between the high-dose propofol group and the positive control group(P>0.05). Conclusion Propofol can effectively reverse the malignant biological behavior of prostate cancer PC3 cell, and its mechanism may be related to the inhibition of the expression of Nrf2/ARE signal pathway related proteins.
作者
张文杰
王祥
徐晓丽
郑荇月
ZHANG Wenjie;WANG Xiang;XU Xiaoli;ZHENG Xingyue(Department of Anesthesiology,Haian People's Hospital,Haian,Jiangsu 226600,China)
出处
《中南医学科学杂志》
CAS
2022年第3期350-353,共4页
Medical Science Journal of Central South China
基金
南通市科技计划(指导性)项目(MSZ18176)。